Comparison and evaluation of cardiac biomarkers in patients with intermittent claudication: Results from the CAVASIC study

Clinical Chemistry

Volumn 59, Issue 4, 2013, Pages 692-702

  Kollerits, Barbara ^a   Sturm, Gisela ^a   Lamina, Claudia ^a   Hammerer Lercher, Angelika ^b   Rantner, Barbara ^a   Stadler, Marietta ^c   Ziera, Tim ^d   Struck, Joachim ^d   Klein Weigel, Peter ^e   Fraedrich, Gustav ^a   Kronenberg, Florian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^c Hietzing Hospital   (Austria)

^d THERMO FISHER SCIENTIFIC   (Germany)

^e Helios Kliniken Berlin Buch   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MIDREGIONAL PROATRIAL NATRIURETIC PEPTIDE; PROADRENOMEDULLIN; PROTEIN C TERMINAL ENDOTHELIN 1 PRECURSOR FRAGMENT; PROTEIN MIDREGIONAL PROADRENOMEDULLIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; MALE; SMOKING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; INTERMITTENT CLAUDICATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIUM; PHENOTYPE;

EID: 84875831114     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.193656     Document Type: Article

References (39)

1. Kollerits B, Heinrich J, Pichler M, Rantner B, Klein- Weigel P, Wolke G, et al. Intermittent claudication in the Erfurt Male Cohort (ERFORT) Study: its determinants and the impact on mortality. A population-based prospective cohort study with 30 years of follow-up. Atherosclerosis 2008;198: 214-22.
2. Lamina C, Meisinger C, Heid IM, Lowel H, Rantner B, Koenig W, Kronenberg F. Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J 2006;27: 2580-7.
3. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
4. Mukherjee D, Cho L. Peripheral arterial disease: considerations in risks, diagnosis, and treatment. J Natl Med Assoc 2009;101:999 -1008.
5. Kitamura K, Eto T. Adrenomedullin-physiological regulator of the cardiovascular system or biochemical curiosity? Curr Opin Nephrol Hypertens 1997;6:80 -7.
6. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
7. Ishimitsu T, Ono H, Minami J, Matsuoka H. Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 2006;111:909 -27.
8. Kobayashi K, Kitamura K, Hirayama N, Date H, Kashiwagi T, Ikushima I, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996;131:676-80.
9. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995;92:286 -9.
10. Kohno M, Hanehira T, Kano H, Horio T, Yokokawa K, Ikeda M, et al. Plasma adrenomedullin concentrations in essential hypertension. Hypertension 1996;27:102-7.
11. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von Eckardstein A, et al. Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009;75:408 -14.
12. Gouya G, Sturm G, Lamina C, Zitt E, Freistatter O, Struck J, et al. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One 2011;6:e17803.
13. Hayashi M, Shimosawa T, Isaka M, Yamada S, Fujita R, Fujita T. Plasma adrenomedullin in diabetes. Lancet 1997;350:1449 -50.
14. Suzuki Y, Horio T, Nonogi H, Hayashi T, Kitamura K, Eto T, et al. Adrenomedullin as a sensitive marker for coronary and peripheral arterial complications in patients with atherosclerotic risks. Peptides 2004;25:1321-6.
15. Suzuki Y, Horio T, Hayashi T, Nonogi H, Kitamura K, Eto T, et al. Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation. Regul Pept 2004;118:99 -104.
16. Arad M, Elazar E, Shotan A, Klein R, Rabinowitz B. Brain and atrial natriuretic peptides in patients with ischemic heart disease with and without heart failure. Cardiology 1996;87:12-7.
17. van den Berg MP, Tjeerdsma G, Jan de Kam P, Boomsma F, Crijns HJ, van Veldhuisen DJ. Longstanding atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced congestive heart failure. Eur J Heart Fail 2002;4:255-62.
18. Horio T, Shimada K, Kohno M, Yoshimura T, Kawarabayashi T, Yasunari K, et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J 1993;126:293-9.
19. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
20. Nunez DJ, Brown MJ, Davenport AP, Neylon CB, Schofield JP, Wyse RK. Endothelin-1 mRNA is widely expressed in porcine and human tissues. J Clin Invest 1990;85:1537-41.
21. Dieplinger B, Gegenhuber A, Struck J, Poelz W, Langsteger W, Haltmayer M, Mueller T. Chromogranin A and C-terminal endothelin-1 precursor fragment add independent prognostic information to amino-terminal proBNP in patients with acute destabilized heart failure. Clin Chim Acta 2009;400:91-6.
22. Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, Cicoira M, et al. Identification of chronic heart failure patients with a high 12-month mortality risk using biomarkers including plasma C-terminal proendothelin- 1. PLoS One 2011;6:e14506.
23. Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, Squire IB, et al. C-terminal proendothelin- 1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J 2007;154: 736-42.
24. Rantner B, Kollerits B, Anderwald-Stadler M, Klein-Weigel P, Gruber I, Gehringer A, et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008;54:851-7.
25. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962;27:645-58.
26. Hammerer-Lercher A, Puschendorf B, Mair J. B-type natriuretic peptides as powerful markers in cardiac diseases-analytical and clinical aspects. J Lab Med 2006;30:165-84.
27. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574-81.
28. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49 -57.
29. Drion I, Kleefstra N, Landman GW, Alkhalaf A, Struck J, Groenier KH, et al. Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and newonset albuminuria in type 2 diabetes? (ZODIAC-29). Diabetes Care 2012;35:2354-8.
30. Kato J, Tsuruda T, Kita T, Kitamura K, Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 2005;25: 2480-7.
31. Silver MA. The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens 2006;15:14 -21.
32. Abraham D, Dashwood M. Endothelin-role in vascular disease. Rheumatology 2008;47(Suppl 5): v23-4.
33. Iglarz M, Clozel M. Mechanisms of ET-1-induced endothelial dysfunction. J Cardiovasc Pharmacol 2007;50:621-8.
34. Hagner S, Haberberger R, Kummer W, Springer J, Fischer A, Bohm S, et al. Immunohistochemical detection of calcitonin gene-related peptide receptor (CGRPR)-1 in the endothelium of human coronary artery and bronchial blood vessels. Neuropeptides 2001;35:58-64.
35. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326: 381-6.
36. Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 2004;172:95-105.
37. Lewis LK, Smith MW, Yandle TG, Richards AM, Nicholls MG. Adrenomedullin(1-52) measured in human plasma by radioimmunoassay: plasma concentration, adsorption, and storage. Clin Chem 1998;44:571-7.
38. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, Vuolteenaho O. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004;50:1576-88.
39. Struck J, Morgenthaler NG, Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 2005;26:2482-6.